CTIS2023-505110-14-00进行中（未招募）1 期
A Phase 2, Randomized Study to Evaluate Safety, Efficacy, and Optimal Dose of ABBV-400 in Combination with Fluorouracil, Folinic Acid, and Bevacizumab in Previously Treated Subjects with Unresectable Metastatic Colorectal Cancer - M24-311
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 206
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Diagnosis of histologically or cytologically confirmed unresectable metastatic colorectal cancer (mCRC)., Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
排除标准
- •Harbor the BRAF V600E mutation., dMMR+/MSI-H., Progressed on only one first-line (1L) systemic treatment of combination chemotherapy in the metastatic setting with or without targeted therapy., Received anticancer therapy including chemotherapy, radiation therapy, immunotherapy, biologic, or any investigational therapy within 28 days or 5 half-lives of the drug (whichever is shorter) prior to the first dose of ABBV-400.
研究者
相似试验
进行中（未招募）
1 期
A Study Evaluating Venetoclax in Combination with Azacitidine Compared with Azacitidine Alone in Subjects with Previously Untreated Higher-Risk Myelodysplastic Syndromes (MDS)EUCTR2016-001657-41-DEAbbVie Deutschland GmbH & Co. KG90
进行中（未招募）
1 期
A Study Evaluating Venetoclax in Combination with Azacitidine Compared with Azacitidine Alone in Subjects with Previously Untreated Higher-Risk Myelodysplastic Syndromes (MDS)EUCTR2016-001657-41-GBAbbVie Deutschland GmbH & Co. KG90
进行中（未招募）
1 期
Evaluating Avelumab in combination with Cetuximab in Head and neck cancer (EACH)recurrent/metastatic head and neck squamous cell cancerMedDRA version: 20.0 Level: PT Classification code 10067821 Term: Head and neck cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10060121 Term: Squamous cell carcinoma of head and neck System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-003592-64-GBniversity College London130
进行中（未招募）
1 期
A study investigating the safety, absorption and elimination of FM101, a new compound in the treatment of non-alcoholic fatty liver disease.onalcoholic Fatty Liver Disease (NAFLD) or Nonalcoholic Steatohepatitis (NASH)MedDRA version: 22.0Level: LLTClassification code 10029530Term: Non-alcoholic fatty liverSystem Organ Class: 10019805 - Hepatobiliary disordersMedDRA version: 22.0Level: PTClassification code 10053219Term: Non-alcoholic steatohepatitisSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2020-005187-63-HUFuture Medicine Co., Ltd.60
进行中（未招募）
1 期
A study investigating the safety, absorption and elimination of FM101, a new compound in the treatment of non-alcoholic fatty liver disease.onalcoholic Fatty Liver Disease (NAFLD) or Nonalcoholic Steatohepatitis (NASH)MedDRA version: 22.0Level: LLTClassification code 10029530Term: Non-alcoholic fatty liverSystem Organ Class: 10019805 - Hepatobiliary disordersMedDRA version: 22.0Level: PTClassification code 10053219Term: Non-alcoholic steatohepatitisSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2020-005187-63-ESFuture Medicine Co., Ltd.60